Using SMART Experimental Design to Personalize Treatment for Child Depression

September 27, 2021 updated by: Dikla Eckshtain, PhD, Massachusetts General Hospital

The purpose of the study is:

  1. To conduct a pilot SMART (Sequential, Multiple Assignment, Randomized) study with the long-term goal of developing a personalized treatment for child depression.
  2. To collect pilot data on ways to personalize treatment for child depression using cognitive behavioral therapy (CBT), caregiver-child treatment, or both.

Study Overview

Detailed Description

Child depression is among the most prevalent and impairing pediatric conditions and constitutes a major public health concern. Unfortunately, treatment benefits are relatively modest and short-lived with sizeable percentages of children who maintain depressive symptoms following treatment. This problem may be addressed in part by personalizing treatment, including determining which children will benefit from CBT, which children will benefit from caregiver-child treatment, and which children will benefit from both. The goal of the current study is to pilot test an innovative experimental design called Sequential, Multiple Assignment, Randomized Trial (SMART), which is used for development of personalized treatments, collect pilot data, and assess the acceptability and feasibility of using this design, in preparation for a full-scale SMART in a larger clinical trial and for the development of personalized treatment.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 10 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Current diagnosis of Major Depressive Disorder (MDD), Dysthymic Disorder (DD), or Depressive Disorder Not Otherwise Specified (NOS).
  2. If receiving psychiatric medication, dose should be stable for at least three months at enrollment.

Exclusion Criteria:

  1. A disorder other than depression as primary diagnosis.
  2. Autism Spectrum Disorders and Pervasive Developmental Delay or Disorder.
  3. Mental Retardation.
  4. Psychotic Disorders and Schizophrenia.
  5. Mania or Hypomania disorders.
  6. Acute suicidal behavior and/or acute plan that require higher level of care, and being hospitalized over the past year for a suicide attempt or for threatening to commit suicide.
  7. Participation in additional psychotherapy.
  8. Caregiver and/or children do not speak English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cognitive Behavioral Therapy (CBT)
Type of talk therapy that focuses on individual behavioral and cognitive skills.
Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
Experimental: Caregiver-Child Treatment
Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Versions (K-SADS-PL)
Time Frame: Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Clinician-administered semi-structured interview with children and caregivers assessing present episode and lifetime history of psychiatric diagnoses based on DSM-IV criteria.
Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Children's Depression Rating Scale-Revised (CDRS-R)
Time Frame: Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Clinician-administered semi-structured child interview of depression.
Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Children's Depression Inventory 2: Self Report (CDI2:SR)
Time Frame: Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Child self-report questionnaire assessing depressive symptoms.
Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Children's Depression Inventory 2:Parent (CDI2:P)
Time Frame: Pre-treatment, Stage 1, Stage 2, 3-month follow-up, before each session
Parent-report questionnaire assessing child's depressive symptoms.
Pre-treatment, Stage 1, Stage 2, 3-month follow-up, before each session
Clinical Global Impression (CGI)
Time Frame: Pre-treatment, Stage 1, Stage 2, 3-month follow-up
Clinician assessment of child's symptom severity and level of improvement.
Pre-treatment, Stage 1, Stage 2, 3-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

November 30, 2018

Study Completion (Actual)

November 30, 2018

Study Registration Dates

First Submitted

June 10, 2013

First Submitted That Met QC Criteria

June 16, 2013

First Posted (Estimate)

June 19, 2013

Study Record Updates

Last Update Posted (Actual)

September 29, 2021

Last Update Submitted That Met QC Criteria

September 27, 2021

Last Verified

August 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 5K23MH093491 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Cognitive Behavioral Therapy (CBT)

Subscribe